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A Na1-dependent neutral and cationic amino acid
transport system (B01) plays an important role in many
cells and tissues; however, the molecular basis for this
transport system is still unknown. To identify new
transporters, the expressed sequence tag database was
queried, and cDNA fragments with sequence similarity
to the Na1/Cl2-dependent neurotransmitter transporter
family were identified. Based on these sequences, rapid
amplification of cDNA ends of human mammary gland
cDNA was used to obtain a cDNA of 4.5 kilobases (kb).
The open reading frame encodes a 642-amino acid pro-
tein named amino acid transporter B01. Human ATB01
(hATB01) is a novel member of the Na1/Cl2-dependent
neurotransmitter transporter family with the highest
sequence similarity to the glycine and proline transport-
ers. Northern blot analysis identified transcripts of ;4.5
kb and ;2 kb in the lung. Another tissue survey suggests
expression in the trachea, salivary gland, mammary
gland, stomach, and pituitary gland. Electrophysiology
and radiolabeled amino acid uptake measurements
were used to functionally characterize the transporter
expressed in Xenopus oocytes. hATB01 was found to
transport both neutral and cationic amino acids, with
the highest affinity for hydrophobic amino acids and the
lowest affinity for proline. Amino acid transport was
Na1 and Cl2-dependent and was attenuated in the pres-
ence of 2-aminobicyclo-[2.2.1]-heptane-2-carboxylic acid,
a system B01 inhibitor. These characteristics are con-
sistent with system B01 amino acid transport. Thus,
hATB01 is the first cloned B01 amino acid transporter.
Amino acids are involved in biosynthetic pathways, act as
neurotransmitters, and are essential for metabolic processes.
Amino acids do not permeate cell membranes and therefore
require specialized transport proteins in order to cross the
plasma membrane (1). Transporters are classified based on
sequence similarity, amino acid substrate specificity, and ion
dependence. Ion-independent transporters carry amino acids
according to their electrochemical gradient, whereas ion-cou-
pled transporters use ion motive force to concentrate amino
acids inside the cell (2).
Mammalian plasma membrane amino acid transporters
have been functionally classified into two groups based on their
Na1-independent or Na1-dependent mechanism of action (3,
4). Two gene families encode transporters that mediate Na1-
independent amino acid transport. One such family, the cati-
onic amino acid transporters, CAT1–CAT4, carries lysine, ar-
ginine, and histidine and possesses much lower affinity for
other amino acids (5). Na1-independent amino acid transport is
also induced by another family of proteins, which include 4f2hc
(6, 7) and rBAT (8, 9). These proteins are not transporters
themselves but rather have recently been shown to form het-
eromultimers with other proteins, y1LAT (10, 11), LAT1 (12),
or xCT (13), which show homology to the CAT family. The
amino acid substrate specificity of these complexes depends on
the specific subunit composition (10–13).
Na1-dependent transporters utilize the electrochemical gra-
dients of Na1 and other ions to actively transport amino acids.
There are two gene families that encode Na1-dependent amino
acid transporters. One Na1-dependent transporter family in-
cludes the excitatory amino acid transporters that transport
glutamate and aspartate, EAAT1–5, the transporters for ala-
nine, serine, and cysteine, ASCT1 and ASCT2, and the neutral
amino acid transporter hATB0 (14, 15). In addition to cotrans-
port of amino acids and Na1, members of this family have been
reported to cotransport H1 and countertransport K1 (16, 17).
An additional amino acid transporter family utilizes Cl2 along
with Na1 to transport amino acids and other organic sub-
strates into the cell (18, 19). The Na1/Cl2-dependent trans-
porter family includes transporters for g-aminobutyric acid-
like substrates (e.g. betaine and taurine), monoamines (e.g.
serotonin and dopamine), and amino acids (e.g. glycine and
proline) (20).
The recent cloning of transporter genes enables correlation
between individual transport proteins and transport systems
described in specific cell types or tissues (21). Transport sys-
tems for amino acids have been classically characterized based
on amino acid specificity, ion dependence, and pharmacological
properties (1). One such transport system, designated B01, is
defined by Na1-dependent transport of both neutral and cati-
onic amino acids (22). System B01 transport has been reported
in mouse blastocysts (22), Xenopus oocytes (23–26), a human
intestinal cell line (27), rabbit small intestine (28), rabbit con-
junctiva (29, 30), rat pituitary gland (31), bullfrog lung (32),
and human lung (33). The molecular basis of this transport
system is yet unknown.
In this study, we report the cloning and functional expres-
sion of a novel human amino acid transporter, hATB01.1
hATB01 is a member of the Na1/Cl2-dependent neurotrans-
mitter transporter family and transports both neutral and cat-
ionic amino acids in a Na1- and Cl2-dependent manner. Sub-
strate specificity and pharmacology indicate that hATB01 is* This work was supported in part by a grant from The National
Alliance for Research on Schizophrenia and Depression.
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the first molecularly characterized system B01 amino acid
transporter.
EXPERIMENTAL PROCEDURES
Molecular Cloning—Gene-specific primers were paired with adaptor
ligated sequence-specific primers, AP1 and AP2, for rapid amplification
of cDNA ends (RACE) (34) using Advantage PolymeraseTM (CLON-
TECH). Primers were originally designed based on GenBank accession
number AA526963 and were subsequently designed based on 59 and 39
RACE clones and correspond to nucleotides 534–558 and 577–596 for 59
RACE and nucleotides 430–455 and 1969–1994 for 39 RACE (Life
Technologies, Inc.). For primary 59 and 39 RACE, a gene-specific primer
was paired with AP1 to amplify mammary Marathon ReadyTM cDNA
(CLONTECH). This PCR product was diluted 1:500 for secondary
RACE reactions using a nested gene-specific primer and AP2. All 59 and
39 RACE products were subcloned into pCR2.1-TOPO and transformed
into TOP10 Escherichia coli using the TOPO-TA cloning kit (Invitrogen,
Carlsbad, CA). Individual colonies were screened for insert size with
PCR using M13 forward and reverse primers. DNA was sequenced at
the University’s Automated DNA Sequencing Facility on a Model 373A
DNA Sequencer using the Taq DyeDeoxyTM Terminator Cycle Sequenc-
ing Kit (Applied Biosystems, Foster City, CA). Lasergene (DNA Star,
Madison, WI) and Basic Local Alignment Search Tool (BLAST) were
utilized for sequence analysis (35). To determine genomic structure, the
BLAST 2 Sequences program was used to align genomic sequences
(GenBank accession numbers AL034411 and Z96810) with the hATB01
cDNA sequence. Protein motifs were identified using ScanProsite (36),
and membrane topology was predicted by TMpred (37) and Kyte-
Doolittle hydrophobicity analysis.
Northern and Master Blots—The probe was synthesized by PCR
amplification of nucleotides 710–1896 of the hATB01 cDNA and labeled
by random priming with [32P]dCTP (Amersham Pharmacia Biotech) to
a specific activity of approximately 1 3 107 cpm/ml using the Random
Prime Labeling Kit (Roche Molecular Biochemicals). After prehybrid-
ization for 30 min at 68 °C in ExpressHybTM solution (CLONTECH), a
human Multiple Tissue Northern blot and a human Master blot
(CLONTECH) were hybridized with the cDNA probe in ExpressHybTM
for 1 and 6 h, respectively. The Northern blot was washed three times
with 23 SSC and 0.05% SDS at room temperature and twice with 0.13
SSC and 0.1% SDS at 50 °C. The Master blot was washed five times in
23 SSC and 1% SDS at 65 °C and twice in 0.13 SSC and 0.5% SDS at
55 °C. Both blots were subsequently exposed to a PhosphorImager
screen (Molecular Dynamics) for 24 h or to autoradiography film for
48 h at 270 °C.
Expression in Xenopus Oocytes—To obtain the open reading frame for
functional analysis, two primers corresponding to nucleotides 74–105
and 2001–2027 of the hATB01 cDNA sequence were designed. PCR
amplification of mammary gland Marathon ReadyTM cDNA with these
primers yielded a single DNA band of ;1.9 kb that was ligated into
pCR2.1-TOPO. For efficient expression in Xenopus oocytes, the hATB01
coding sequence was transferred into pKSPA, a modified pBluescript
KS1 plasmid (Stratagene, La Jolla, CA) containing (A)30, using XbaI
and HindIII sites. One clone was subsequently used for all functional
studies. The template for cRNA synthesis was prepared by NotI diges-
tion of hATB01-pKSPA or by PCR of hATB01-pKSPA using M13 for-
ward and reverse primers. cRNA was synthesized in vitro with T7 RNA
polymerase (mMessage mMachine; Ambion, Austin, TX). Xenopus oo-
cytes were surgically removed, treated, and selected as described pre-
viously (38, 39). In brief, Xenopus laevis (Nasco, Fort Atkinson, WI)
were anesthetized with 0.2% Tricaine. Oocytes were removed and
treated with 4 mg/ml type 1A collagenase (Sigma) in a Ca2 -free solution
(82.5 mM NaCl, 2 mM KCl, 1 mM MgCl2, and 5 mM HEPES (pH 7.5) with
50 mg/ml gentamycin) for 1 h at room temperature. Oocytes were rinsed
with the Ca21-free solution and then rinsed with modified Ringer’s
solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, and 5 mM
HEPES, pH 7.5) supplemented with 0.5 mM pyruvate and 50 mg/ml
gentamycin. Stage IV oocytes were selected and injected the following
day with 5–10 ng of cRNA or water in a total volume of 50 nl. Oocytes
were maintained at 19 °C in Ringer’s solution supplemented with 0.5
mM pyruvate and 50 mg/ml gentamycin. Three to seven days after
injection, oocytes were used for electrophysiology or uptake experi-
ments. All experiments were performed at room temperature (21 °C).
Electrophysiology—Two electrode voltage clamp experiments were
conducted using a GeneClamp 500 amplifier (Axon Instruments, Foster
City, CA). Current was measured upon application of increasing con-
centrations of amino acids ranging from 1 mM to 10 mM for ;15 s and
washed for a period of ;30 s in Ringer’s solution. In ion dependence
experiments, the NaCl concentration of the Ringer’s solution was 100 mM,
and Na1 and Cl2 were substituted with equimolar concentrations of
N-methyl-D-glucamine and gluconate, respectively. All experiments were
conducted at a holding potential of 280 mV. Clampex was used to acquire
data at 62.5 Hz (pClamp 6; Axon Instruments). After digital filtering at 1
Hz, data were analyzed by Clampfit (pClamp 6; Axon Instruments).
Uptake Experiments—L-[4,5-3H]Leucine (136 Ci/mmol), L-[2,3,4,5-
3H]arginine monohydrochloride (71 Ci/mmol), and L-[G-3H]glutamic acid
(136 Ci/mmol) (Amersham Pharmacia Biotech) were diluted to a concen-
tration of 90 nM and used to assess amino acid uptake. After incubation
with 3H-amino acid in the appropriate Ringer’s solution, oocytes were
immediately washed four times with the same ice-cold solution, individ-
ually solubilized in 1% SDS, and counted by liquid scintillation. Initial
time course experiments of L-[3H]leucine transport indicated that uptake
was linear from 1–10 min (data not shown); consequently, time points
of 2 or 5 min were chosen. For ion dependence experiments, oocytes
were initially rinsed three times in Na1 or Cl2-free solution.
RESULTS AND DISCUSSION
hATB01 Cloning Strategy—Sequence homology is commonly
used to identify novel genes of emerging gene families. The
expressed sequence tag (EST) database was queried to identify
new members of the Na1/Cl2-dependent transporter family.
After the identification of an EST (GenBank accession number
AA526963) from mammary gland cDNA with homology to this
family, RACE of human mammary gland Marathon ReadyTM
cDNA was performed to clone the full-length gene. hATB01
cDNA is 4.5 kb in length and has been submitted to GenBank
(GenBank accession number AF151978). hATB01 possesses ab-
solute identity with human ESTs (GenBank accession numbers
AA526963, AA552658, and AA541466) and is highly similar
(;90%) to mouse ESTs (GenBank accession numbers
AI006618, AI006510, AA592728, AI1429024, and AI605513).
Primary Structure—hATB01 is a member of the Na1/Cl2-de-
pendent neurotransmitter transporter family and shows the
highest similarity (;60%) to the glycine transporters GLYT1
(40–42) and GLYT2 (43) and the proline transporter PROT
(44). The isolated hATB01 cDNA contains an open reading
frame of 1926 base pairs, which predicts a protein of 642 amino
acids (Fig. 1A). Hydrophobicity prediction (37, 45) of the pri-
mary amino acid sequence suggests 12 putative membrane-
spanning domains, similar to other Na1/Cl2-dependent trans-
porters (Fig. 1A). Analysis of the amino acid sequence by
ScanProsite (36) reveals several consensus sites for post-trans-
lational modification (Fig. 1A). There are seven possible glyco-
sylation sites on the second putative extracellular loop and one
on the third putative extracellular loop. Two consensus sites for
protein kinase C phosphorylation are located at Ser-40 and
Ser-261. The Ser-40 site is also present in the amino acid
transporters hGLYT2 and hPROT, and the protein kinase C
consensus site located at Ser-261 is highly conserved among
the Na1/Cl2-dependent neurotransmitter transporter family
(20). Phorbol esters, protein kinase C activators, have been
reported to regulate Na1/Cl2-dependent transporter activity
(46–50) and membrane localization (51, 52). However, regula-
tion may or may not be mediated by direct phosphorylation by
protein kinase C (47, 53). hATB01 also shows a consensus site
for phosphorylation by casein kinase II in the fourth putative
intracellular loop at Thr-434.
Genomic Structure—Periodic query of GenBank revealed
genomic sequences that were identical to hATB01 (GenBank
accession number AL034411 and Z96810), and alignment with
hATB01 cDNA predicts the gene structure. The coding se-
quence possesses 14 exons, each of which is ;100–200 base
pairs in length (Fig. 1B). Genomic organization is conserved
among members of the Na1/Cl2-dependent transporter family,
and the coding sequence of the transmembrane domains is not
interrupted by introns (54). The genomic sequences (GenBank
accession numbers AL034411 and Z96810) were assigned to
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chromosome X at positions Xq24 and Xq22.1–23, respectively.
Interestingly, several forms of nonspecific mental retardation
and other central nervous system disorders have been mapped
to this region (55–62).
Tissue Distribution—A human Master blot was probed to
determine the tissue distribution of hATB01 mRNA. The high-
est expression was detected in the lung, fetal lung, trachea, and
salivary gland, and lower levels of expression were detected in
the mammary gland, stomach, and pituitary gland. Hybridiza-
tion in the colon, uterus, prostate, and testis was very low (Fig.
2A). ESTs from human mammary gland, colon, and prostate
and from mouse colon are in agreement with the Master blot
tissue distribution data. A multiple tissue Northern blot
showed no expression in the heart, brain, placenta, liver, skel-
etal muscle, kidney; or pancreas; however, transcripts of ;4.5
and ;2 kb were detected in the lung (Fig. 2B). The predomi-
nant transcript of ;4.5 kb corresponds to the length of the
hATB01 isolated cDNA, 4.5 kb.
Functional Studies—The application of substrate generated
ionic current for all members of the Na1/Cl2-dependent trans-
porter family studied electrophysiologically (63). We therefore
utilized a two-electrode voltage clamp to functionally charac-
terize hATB01 in the Xenopus oocyte expression system. Oo-
cytes injected with hATB01 cRNA generated inward current in
response to the application of neutral and cationic amino acids.
The negatively charged amino acids, glutamate and aspartate,
evoked no current. We never observed a current greater than 2
nA in uninjected or water-injected oocytes in response to the
application of 1 mM of each amino acid. Despite some seasonal
and batch-to-batch variation in expression levels, more than 20
batches of oocytes injected with hATB01 cRNA responded to
neutral and cationic amino acids. Amino acid-induced inward
current was observed at all voltages from 2140 to 140 mV, and
the current was increased at more negative potentials (data not
shown). Fig. 3A illustrates the typical current evoked by in-
creasing concentrations of amino acid (1 mM to 1 mM of pheny-
lalanine). Dose-response data for all amino acids that gener-
ated current were saturable. Data were initially fit to the Hill
equation, and Hill coefficients were determined to be approxi-
mately 1. Subsequently, data were fit to a curve assuming a
Hill coefficient equal to 1. Table I presents the EC50 values for
all amino acids evoking transport current. hATB01 preferred
hydrophobic amino acids but also had significant affinity for
other neutral and cationic amino acids. The apparent affinity
for nonpolar amino acids seems to increase with R group size, and
the apparent affinity for polar amino acids seems to decrease
with R group size. The affinity for proline was very low (EC50 .
5 mM) and probably would not be physiologically relevant.
In addition to the 20 naturally occurring amino acids, related
compounds with modified side chain or “core” amino acid struc-
ture were tested. D-Tyrosine evoked transport current with an
EC50 . 1 mM compared with L-tyrosine with an EC50 of 92 mM,
indicating that hATB01 recognizes amino acids stereospecifi-
cally. In addition, b-alanine and 3,4-dihydroxyphenylalanine
(but not g-aminobutyric acid, choline, taurine, and thyroxine)
evoked inward current at concentrations of 1 mM (data not
shown). hATB01 had broad substrate specificity compared with
its most similar family members, GLYT1 and GLYT2, which
only transport glycine and glycine derivatives (40, 43), and
PROT, which transports proline with the highest affinity but
also transports phenylalanine, histidine, and cysteine (44). In-
terestingly, an insect K1-coupled amino acid transporter,
KAAT1, with sequence similarity to this family was also found
to transport a broad range of amino acids (64).
The current generated by amino acid application is believed
to reflect transport across the plasma membrane, but in order
to verify the physical translocation of the amino acid into the
cell, 3H-amino acid uptake experiments were conducted (Fig. 3,
B–D). Consistent with electrophysiological data, oocytes in-
jected with hATB01 cRNA showed higher uptake rates for
L-[3H]leucine and L-[3H]arginine but not for L-[3H]glutamate
when compared with uninjected oocytes (Fig. 3, B and C). The
difference in uptake rate between leucine and arginine (Fig. 3,
B and C) is in agreement with the differences in EC50 values
between leucine- and arginine-induced transport current (Ta-
ble I). L-[3H]Leucine uptake was significantly attenuated in the
presence of 1 mM leucine (data not shown), 1 mM L-arginine,
and 1 mM L-glutamine, but not in the presence of 1 mM L-
glutamate (Fig. 3B). L-[3H]Arginine transport was inhibited by
1 mM L-leucine (Fig. 3C). Because arginine inhibited uptake of
FIG. 1. hATB01 primary structure
and genomic organization. A, hATB01
cDNA encodes a protein of 642 amino ac-
ids and possesses 12 putative transmem-
brane domains (underlined) determined
by the TMpred program (37) and align-
ment with other Na1/Cl2-dependent
neurotransmitter transporters. hATB01
contains eight consensus sites for N-gly-
cosylation represented by f at amino ac-
ids 155, 163, 174, 189, 197, 202, and 230
in the second putative extracellular loop
and at amino acid 302 in the third puta-
tive extracellular loop. Potential protein
kinase C consensus sites (Ser-40 and Ser-
261) are indicated by l. One casein ki-
nase II consensus site (Thr-434) is de-
picted by E. B, alignment of the cDNA
sequence with the genomic sequences
(GenBank accession numbers AL034411
and Z96810) from chromosome X, regions
Xq24 and Xq22.1–23, respectively, pre-
dicts 14 exons of 100–200 base pairs. Cod-
ing regions, f; untranslated regions, M.
Arrows indicate putative transmembrane
domains.
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L-[3H]leucine, and leucine inhibited uptake of L-[3H]arginine,
we conclude that both of these amino acids are carried by the
same transport system. The difference in L-[3H]leucine inhibi-
tion by arginine and glutamine (90% and 63%, respectively) is
probably a result of the difference in their apparent affinity for
hATB01 (Table I). Uptake experiments demonstrated that
hATB01 transports neutral and cationic amino acids (e.g. argi-
nine and leucine). The combination of electrophysiology and
uptake experiments indicates that the current measured rep-
resents the transport process. The transport current measure-
ments can therefore be used to assess hATB01 substrate spec-
ificity and affinity for all amino acids tested.
Pharmacological studies are an important tool for amino acid
transport system classification. High concentrations (5–10 mM)
of 2-aminobicyclo-[2.2.1]-heptane-2-carboxylic acid (BCH), a
cyclic amino acid, have been shown to inhibit system B01
amino acid transport (21–24, 26). In Fig. 3D, 10 mM BCH
significantly inhibited hATB01-mediated L-[3H]leucine uptake
FIG. 2. Tissue distribution of hATB01 mRNA. A, hybridization of a 32P-labeled cDNA probe to a human Master blot (CLONTECH) was used
to determine the tissue distribution of hATB01 mRNA. amygd, amygdala; caud, caudate nucleus; cereb, cerebellum; frlb, frontal lobe; hippo,
hippocampus; md-ob, medulla oblongata; occip, occipital lobe; putam, putamen; sub-n, substantia nigra; temp, temporal lobe; thal, thalamus; stn,
subthalamic nuclei; sp-cd, spinal cord; sk-mu, skeletal muscle; bladr, bladder; uter, uterus; prost, prostate; stom, stomach; pancr, pancreas; pitu,
pituitary; adren, adrenal gland; thyr, thyroid gland; saliv, salivary gland; mam, mammary gland; kidny, kidney; sm-int, small intestine; thym,
thymus; leuk, peripheral leukocyte; bone, bone marrow; appen, appendix; trach, trachea; plac, placenta. Bottom row samples are negative controls:
yeast total RNA, yeast tRNA, E. coli rRNA, E. coli DNA, Poly r(A), and human Cot1 DNA. Positive controls include 100 and 500 ng of human DNA.
The highest level of expression was detected in the lung, fetal lung, trachea, and salivary gland, and lower levels of expression were detected in
the mammary gland, stomach, and pituitary gland. Hybridization in the colon, uterus, prostate, and testis was weak but detectable. B,
hybridization with the same probe to a Multiple Tissue Northern blot (CLONTECH) revealed two transcripts of ;4.5 and ;2 kb in the lung.
FIG. 3. Amino acid specificity of
hATB01. A, a Xenopus oocyte expressing
hATB01 was voltage clamped at 280 mV.
Superfusion of increasing concentrations
of phenylalanine (1 mM to 1 mM, as indi-
cated) generated increasing inward cur-
rent. For B and C, hATB01-injected oocytes
are represented by f, and uninjected oo-
cytes are represented by M. B, oocytes
were incubated for 2 min in the presence
of 90 nM L-[3H]leucine or L-[3H]glutamate
in Ringer’s solution alone or Ringer’s so-
lution containing 1 mM competing amino
acid. Injection of hATB01 cRNA increased
the uptake of L-[3H]leucine but not L-[3H]
glutamate compared with uninjected
cells. hATB01 transport of L-[3H]leucine is
inhibited by L-arginine and L-glutamine
but not L-glutamate. Bars represent the
mean of 10 oocytes 6 S.E. C, oocytes were
incubated for 2 min in the presence of 90
nM L-[3H]arginine in Ringer’s solution
alone or Ringer’s solution supplemented
with 1 mM L-leucine. L-[3H]Arginine uptake
was inhibited in the presence of 1 mM L-
leucine. Bars represent the mean of 10 oo-
cytes 6 S.E. D, oocytes were incubated for
5 min in the presence of 90 nM L-[3H]
leucine in Ringer’s solution or Ringer’s so-
lution supplemented with 10 mM BCH.
BCH significantly inhibits L-[3H]leucine
uptake. Bars represent the mean of 10 oo-
cytes 6 S.E.
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by 67%. BCH was also evaluated electrophysiologically; the
application of 10 mM BCH resulted in an inward current of
5.8 6 1.8 nA (mean 6 S.E.; n 5 3). Because BCH generates
current and inhibits L-[3H]leucine uptake, it is probably a com-
petitive substrate for hATB01.
Members of the Na1/Cl2-dependent transporter family re-
quire both Na1 and Cl2 for transport to occur (65). Fig. 4A
illustrates that hATB01 L-[3H]leucine transport was strongly
dependent on Na1 and Cl2 ions. The hATB01-related compo-
nent of L-[3H]leucine uptake was found to decrease by .99% in
Na1-free and Cl2-free solutions. In agreement with uptake
data, no transport current was measured in Na1-free solution
(Fig. 4B, inset). On the other hand, a small but significant
current was generated by 100 mM leucine in Cl2-free solution.
This current was approximately 6% of the total current evoked
in the presence of 108 mM Cl2 (Fig. 4C, inset). A similar small
Cl2-independent current was also reported for the g-aminobu-
tyric acid transporter, GAT1, expressed in Xenopus oocytes
(39), indicating that external Cl2 is not absolutely required for
some transport to occur. Fig. 4, B and C, describes the effect of
increasing concentrations of Na1 or Cl2 on L-leucine (100 mM)-
induced transport current. Dose-response curves were fitted to
the Hill equation. For Na1, a Hill coefficient of 2.3 6 0.13, an
EC50 of 7.4 6 0.24 mM, and an Imax of 31 6 1.6 nA were
determined (mean 6 S.E.; n 5 5). The Cl2 data yielded a Hill
coefficient of 0.92 6 0.07, an EC50 of 0.61 6 0.03 mM, and an
Imax of 32 6 2.5 nA (mean 6 S.E.; n 5 5). EC50 values of 7.4 and
0.61 mM for Na1 and Cl2, respectively, indicate that under phys-
iological conditions, these ions are not rate-limiting for amino
acid transport. A Hill slope of .2 for Na1 suggests that the
transport cycle involves the binding of at least two Na1 ions, and
Hill slopes for Cl2 and amino acids close to 1 suggest the binding
of one Cl2 ion and one amino acid. Therefore, we propose a
transport stoichiometry of 2 or 3 Na1, 1 Cl2, and 1 amino acid.
Possible Physiological Significance of hATB01—Amino acid
transport through hATB01 can be summarized by the following
characteristics: 1) inward current associated with neutral and
cationic amino acid application; 2) uptake of and competitive
inhibition by neutral and cationic amino acids but not anionic
amino acids; 3) low affinity for proline; 4) uptake inhibition by
the competitive substrate BCH (5–10 mM); and 5) Na1 and Cl2
dependence. The properties of hATB01 are similar to the prop-
erties of a transport system originally described in mouse blas-
tocysts, system B01 (22, 66, 67). System B01is defined by Na1-
coupled transport of neutral and cationic amino acids. This
transport system also shows sensitivity to BCH at high concen-
trations (5–10 mM) (22–24, 26). The similarity of amino acid
specificity, ion dependence, and BCH sensitivity suggest that
hATB01 is the first transporter to possess all system B01
characteristics.
System B01-like transport has also been reported in Xenopus
oocytes (23–26), a human intestinal cell line (27), rabbit small
intestine (28), rabbit conjunctiva (29, 30), rat pituitary gland
TABLE I
Concentration-dependent amino acid-induced transport current
Oocytes expressing hATB01 were voltage clamped at 280 mV and
subjected to increasing concentrations of amino acid ranging from 1 mM
to 10 mM. (See representative experiment in Fig. 3A). Data from indi-
vidual oocytes were fit to the Michaelis-Menten equation, and EC50




Isoleucine 6 6 1
Leucine 12 6 2
Methionine 14 6 1
Valine 36 6 2
Alanine 99 6 36
Glycine 111 6 30
Proline .5 mM
Polar
Serine 43 6 5
Cysteine 118 6 33
Asparagine 348 6 84
Threonine 405 6 80
Glutamine 633 6 62
Aromatic
Phenylalanine 17 6 1
Tryptophan 26 6 6
Tyrosine 92 6 10
Charged
Histidine 76 6 20
Lysine 100 6 1
Arginine 104 6 35
Aspartate N/Da
Glutamate N/D
a N/D, not detectable.
FIG. 4. Amino acid transport is Na1- and Cl2-dependent. A,
hATB01-injected oocytes (f) and uninjected oocytes (M) were incubated
in the presence of 90 nM L-[3H]leucine in Ringer’s solution, Na1-free
solution (N-methyl-D-glucamine substitution), or Cl2-free solution (glu-
conate substitution). Na1 and Cl2 substitution virtually eliminated
hATB01-mediated L-[3H]leucine uptake (;99%). B and C, hATB01-
injected oocytes were voltage clamped at 280 mV. Current was re-
corded during the application of 100 mM L-leucine in the presence of
increasing concentrations of Na1 (B) or Cl2 (C). Inset, an oocyte voltage
clamped at 280 mV in response to 100 mM L-leucine in Ringer’s solution,
Na1-free solution, or Cl2-free solution. Data from individual oocytes
were fit to the Hill equation. B, for Na1 dose-response experiments, a
Hill coefficient of 2.3 6 0.13, an EC50 of 7.4 6 0.24 mM, and an Imax of
31 6 1.6 were determined (mean 6 S.E.; n 5 5). C, for Cl2 substitution
experiments, the Hill coefficient, EC50, and Imax were 0.92 6 0.07,
0.61 6 0.03 mM, and 32 6 2.5 nA, respectively (mean 6 S.E.; n 5 5).
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(31), bullfrog lung (32), and human lung (33). Several studies
have shown system B01 amino acid transport in Xenopus oo-
cytes (23–26), and these data are confirmed by our results. In
the presence of 1 mM arginine or leucine, the endogenous up-
take of L-[3H]leucine (Fig. 3B) and L-[3H]arginine (Fig. 3C),
respectively, was attenuated. BCH inhibited L-[3H]leucine up-
take by uninjected cells (54%) (Fig. 3D). Endogenous L-[3H]
leucine uptake was also Na1- and Cl2-dependent (Fig. 4A).
These data, specifically the Cl2 dependence of L-[3H]leucine
uptake, suggest the expression of a hATB01-like transporter in
Xenopus oocytes.
The pituitary gland is of special interest because amino acids
(e.g. arginine and leucine) are known to act as secretagogues for
anterior pituitary hormones (68). Amino acid-induced hormone
secretion was found to be induced by an intracellular rise in
Ca21 and dependent on extracellular Na1 (31). Based on the
amino acid specificity that caused an increase in intracellular
Ca21, Villalobos et al. (31) hypothesized that the amino acid
influx is through a Na1-dependent transporter. Similar sub-
strate specificity and the possible expression of hATB01 in the
pituitary gland suggest that hATB01 may play a role in amino
acid-induced pituitary secretion. A transporter could regulate
hormone secretion as a direct result of Na1, Cl2, or amino acid
influx or due to depolarization of the cell membrane. These
hypotheses are currently being investigated in our laboratory.
Transport measurements in lung epithelial cells provide the
strongest evidence for hATB01-mediated system B01 amino
acid transport. Galietta et al. (33) reported a potential B01
transport system in cultured human bronchial epithelial cells
using uptake and short circuit current measurements. They
observed Na1-dependent transport current in response to the
application of L-arginine, L-lysine, and L-alanine with EC50
values of 80, 66, and 26 mM, respectively, and a much lower
affinity for proline. Also, L-aspartate and taurine did not pro-
duce short circuit current in these cells. The reported amino
acid transport in human bronchial epithelial cells may be me-
diated by hATB01 due to its high expression in the lung and
corresponding substrate specificity and affinity. Therefore,
hATB01 could play a significant role in the removal of amino
acids, Na1, and Cl2 from the airway surface liquid. Localiza-
tion of mRNA and protein and more extensive functional meas-
urements will determine whether hATB01 underlies the amino
acid transport in the lung, pituitary gland, and other tissues in
which system B01-like amino acid transport has been described.
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